Project Details
Description
DESCRIPTION: (provided by applicant) Infection with the human T-cell leukemia
virus type 1 (HTLV-1) can have diverse clinical effects. ranging from
asymptomatic infection to the development of the fatal malignancy, adult T-cell
leukemia/lymphoma (ATL) HTLV-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), or a variety of autoimmune dnd inflammatory diseases. The
differential pathogenesis of these disorders undoubtedly involves complex
interactions between HTLV-1 and the infected host. These interactions are
likely to be both at the level of the whole organism (i.e. immune response to
the virus) and at the level of the individual infected cell, in which cellular
regulatory mechanisms could influence viral gene expression. Recent studies
from our laboratory have demonstrated that HTLV1 infection of human T cell
lines can be essentially latent, with only very low levels of HTLV-1 gene
expression. HTLV-1 gene expression can be activated from latently infected cell
lines by treatment with immune activation related stimuli, such as
phytohemagglutinin (PHA) and phorbol esters (PMA). We have further shown a
marked, synergistic activation of HTLV- 1 gene expression induced by T-cell
activation stimuli in conjunction with the HTLV-1 Tax transcriptional
transactivator. These data suggest interesting models for regulation of HTLV-1
gene expression by cellular activation stimuli and an overall hypothesis that
immune activation stimuli may enhance HTLV-1 gene expression. thus contributing
to the development of diseases such as ATL. Immune stimulation of infected I
cells would enhance expression of HTLV-1 gene products, such as the oncogenic
Tax protein Tax expression in turn would induce T cell proliferation, leading
to the poly-. and oligoclonal T cell proliferation associated with HTLV-1
induced neurologic and autoimmune disease, and ultimately to the monoclonal
proliferation of AlL. In this project, we will examine the mechanisms
responsible for the induction of HTLV-1 gene expression by immune activation
stimuli and the possible biological implications of this activation, as they
may contribute to disease pathogenesis. The specific aims of the project are
to: (1) Characterize the molecular mechanisms by which immune activation
stimuli induce HTLV-1 gene expression, focusing on the roles of the HTLV-1 LTR
and HTLV-1 Tax in the synergistic activation induced by immune activation
stimuli; (2) Study the effects of viral LTR sequences and immune activation
stimuli on HTLV 1 replication and T-cell transformation; (3) Determine if
HTLV-1 lax will cooperate with immune 'activation stimuli in the regulation of
cellular target genes that may contribute to HTLV-1 pathogenesis and
oncogenesis: and (4) Determine if immune activation stimuli will induce T cell
lymphomas in HTLV-1 LTR-Tax transgenic mice. thus providing a possible model of
events involved in the pathogenesis of human AlL.
Status | Finished |
---|---|
Effective start/end date | 12/7/01 → 11/30/07 |
Funding
- National Cancer Institute: $274,095.00
- National Cancer Institute: $270,871.00
- National Cancer Institute: $267,541.00
- National Cancer Institute: $274,316.00
- National Cancer Institute: $274,207.00
ASJC
- Genetics
- Molecular Biology
- Cancer Research
- Immunology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.